1. Anderson LO, Barrowcliffe TW, Holmer E, Johnson EA, Sims GEC Anticoagulant properties of heparin fractionated by affinity chromatography on matrix bound antithrombin III and by gel fraction. Thromb Res 9, 575–581, 1976.
2. Babior BM. Oxidants from phagocytes: agents of defense and destruction. Blood 64, 959, 1984.
3. Bazzoni G, Beltran Nunez A, Bianchini P, Mascellani G, Dejana E, Del Maschio A. Modulation of human polymorphonuclear leukocyte function by heparin and dermatan sulfate (In press).
4. Bianchini P, Osima B, Parma B. Lack of correlation of some pharmacological activities of heparin with in vitro and in vivo tests. In: Ricci G et al. (Eds). Therapeutic selectivity and risk/benefit assessment of hypolipidemic drugs. Raven Press New York, pp 195–199, 1982.
5. Bianchini P, Osima B, Parma B, Nader HB, Dietrich CP. Lack of correlation between in vitro and in vivo antithrombotic activity of heparin fractions and related compounds. Heparan sulfate as an antithrombotic agent in vivo. Thromb Res 40, 597–607, 1985.